242 related articles for article (PubMed ID: 17317861)
1. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
3. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
[TBL] [Abstract][Full Text] [Related]
4. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases.
Elliott J; Suessmuth Y; Scott LM; Nahlik K; McMullin MF; Constantinescu SN; Green AR; Johnston JA
Haematologica; 2009 Apr; 94(4):576-80. PubMed ID: 19229050
[TBL] [Abstract][Full Text] [Related]
5. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
7. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses.
Suessmuth Y; Elliott J; Percy MJ; Inami M; Attal H; Harrison CN; Inokuchi K; McMullin MF; Johnston JA
Br J Haematol; 2009 Nov; 147(4):450-8. PubMed ID: 19735488
[TBL] [Abstract][Full Text] [Related]
8. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
10. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.
Dusa A; Staerk J; Elliott J; Pecquet C; Poirel HA; Johnston JA; Constantinescu SN
J Biol Chem; 2008 May; 283(19):12941-8. PubMed ID: 18326042
[TBL] [Abstract][Full Text] [Related]
11. JAK2, the JAK2 V617F mutant and cytokine receptors.
Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
[TBL] [Abstract][Full Text] [Related]
12. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
13. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
Funakoshi-Tago M
Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
[TBL] [Abstract][Full Text] [Related]
15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
16. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
[TBL] [Abstract][Full Text] [Related]
17. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
[TBL] [Abstract][Full Text] [Related]
18. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
[TBL] [Abstract][Full Text] [Related]
20. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]